Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial - JSON Representation

Raw json | Download

{
  "resourceType" : "Evidence",
  "id" : "179635",
  "meta" : {
    "versionId" : "7",
    "lastUpdated" : "2024-12-13T21:07:33.593Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-participant-flow-evidence"
    ]
  },
  "text" : {
    "status" : "empty",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"
  },
  "url" : "https://fevir.net/resources/Evidence/179635",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "urn:ietf:rfc:3986",
      "value" : "https://fevir.net/FOI/179635",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "name" : "ComparativeParticipantFlowEvidence_Dropout_due_to_stopping_intervention_Lofexidine_vs_Placebo_in_opioid_detoxification_trial",
  "title" : "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial",
  "status" : "active",
  "publisher" : "Computable Publishing LLC",
  "contact" : [
    {
      "telecom" : [
        {
          "system" : "email",
          "value" : "support@computablepublishing.com"
        }
      ]
    }
  ],
  "author" : [
    {
      "name" : "Brian S. Alper"
    }
  ],
  "useContext" : [
    {
      "code" : {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "evidence-communication",
        "display" : "Evidence Communication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "ComparativeParticipantFlowEvidence",
            "display" : "ComparativeParticipantFlowEvidence"
          }
        ]
      }
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "relatedArtifact" : [
    {
      "type" : "cite-as",
      "citation" : "ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial [Database Entry: FHIR Evidence Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179635. Revised 2024-05-16. Available at: https://fevir.net/resources/Evidence/179635. Computable resource at: https://fevir.net/resources/Evidence/179635#json."
    },
    {
      "type" : "derived-from",
      "resourceReference" : {
        🔗 "reference" : "Citation/179637",
        "type" : "Citation",
        "display" : "18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal"
      }
    }
  ],
  "description" : "Dropout due to stopping intervention 18/33 with Lofexidine vs. 12/35 with Placebo in opioid detoxification trial",
  "variableDefinition" : [
    {
      "description" : "Participants in the opioid detoxification trial",
      "variableRole" : "population"
    },
    {
      "description" : "GroupAssignment: Lofexidine vs. Placebo",
      "variableRole" : "exposure",
      "comparatorCategory" : "false"
    },
    {
      "description" : "Dropout due to stopping intervention",
      "variableRole" : "outcome",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/179636",
        "type" : "EvidenceVariable",
        "display" : "PartiicipantFlowMeasure: Dropout due to stopping intervention"
      }
    }
  ],
  "statistic" : [
    {
      "description" : "18/33 (54.5%) with Lofexidine vs. 12/35 (34.3%) with Placebo (relative risk 1.59, p < 0.01)",
      "statisticType" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/181513",
            "code" : "STATO:0000245",
            "display" : "Risk Ratio"
          }
        ]
      },
      "quantity" : {
        "value" : 1.59
      },
      "numberAffected" : 30,
      "sampleSize" : {
        "numberOfParticipants" : 68
      },
      "attributeEstimate" : [
        {
          "description" : "p < 0.01",
          "type" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/181513",
                "code" : "STATO:0000700",
                "display" : "p-value"
              }
            ]
          },
          "quantity" : {
            "value" : 0.01,
            "comparator" : "<"
          }
        }
      ]
    }
  ]
}